So-Young International runs China's largest online platform for cosmetic and aesthetic medical procedures, connecting consumers with licensed clinics and surgeons and monetising through advertising, transaction fees and its consumer-facing content and reviews. The structural case rests on the aesthetic medicine market's shift toward online discovery and booking, where So-Young's brand and review base give it a traffic advantage over smaller rivals, and on a gross margin of 46.0% that suggests its marketplace model is pricing reasonably well. Revenue grew 45.6% over the last year, and the stock trades on a forward P/E of 16.3, a sharp contrast with an operating margin of -13.4% and an ROE of -15.0%, so the multiple is only meaningful if the company converts that top-line momentum into operating profit. The near-term question is whether operating losses narrow as revenue scales, which is the single variable a deeper look should test. At a market cap of $235M and no index membership, the name sits in a thin-coverage corner of the market, where a turn in profitability could reprice the stock quickly in either direction. The composite score of 53/100 signals a mixed profile rather than a clear screen pass, so the work ahead is to separate durable growth from growth bought with losses.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 15 Oct 2026, 00:00 CEST | ACCE price target | $2.60 | first publication | $2.65 |
Answered from So-Young International Inc. American Depository Shares fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| SY So-Young International Inc. American Depository Shares | $2.11 | - | - | - | -15.0% | 43 | 48 |
| SPOK Spok Holdings Inc. Common Stock | $10.30 | $12 | 17% below | 18.8x | 8.4% | 75 | 48 |
| ASCN.SW Ascom Holding AG | CHF 5.72 | CHF 7 | 20% below | 11.0x | 25.7% | 78 | 73 |
| AMWL American Well Corporation Class A Common Stock | $13.57 | - | - | - | -29.1% | 43 | 42 |
| CARA.ST Carasent AB (publ) | kr 27.00 | kr 15 | 84% above | 45.8x | 4.8% | 66 | 58 |
| OPRX OptimizeRx Corporation Common Stock | $9.15 | $9 | 3% below | 38.1x | 3.7% | 54 | 51 |
| SUS.ST Surgical Science Sweden AB (publ) | kr 57.20 | kr 56 | 2% above | 31.4x | 2.1% | 70 | 63 |
Where SY ranks against its sector peers on each metric.